Equity Overview
Price & Market Data
Price: $2.30
Daily Change: +$0.15 / 6.52%
Daily Range: $2.27 - $2.31
Market Cap: $2,993,754
Daily Volume: 3,104
Performance Metrics
1 Week: 12.27%
1 Month: -8.26%
3 Months: -29.50%
6 Months: -46.25%
1 Year: -51.14%
YTD: -23.49%
Details
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.